Early cancer detection has long been the holy grail of oncology, but translating a promising blood test into a population-wide screening tool demands a level of evidence that goes well beyond sensitivity and specificity metrics. Two landmark studies now offer the most rigorous real-world data yet on multi-cancer early detection (MCED) tests — and the picture is more complicated than either proponents or skeptics anticipated.
The PATHFINDER 2 and NHS-Galleri trials examined the clinical performance, safety profiles, and implementation realities of cell-free DNA-based MCED testing across large, geographically distinct cohorts. Both studies evaluated the Galleri test, which screens for dozens of cancer types simultaneously through methylation signal analysis of circulating tumor DNA. Together, they provide complementary datasets on positive predictive value, false-positive rates, downstream diagnostic workup burden, and the proportion of cancers detected at earlier, potentially more treatable stages. Critically, neither trial was powered to demonstrate the ultimate metric that regulators and public health bodies require: a statistically significant reduction in cancer mortality at the population level.
This distinction matters enormously. MCED tests have generated extraordinary commercial momentum, with several products approaching or already in limited clinical use, yet the evidentiary bar for population screening — showing that earlier detection actually translates into fewer deaths — remains uncleared. The NHS-Galleri trial is among the first randomized efforts designed to approach this question, but definitive mortality data will require years of follow-up. In the interim, clinicians face pressure to adopt tools whose net benefit is still being established. False positives, which trigger invasive and costly diagnostic cascades, represent a non-trivial harm that must be weighed against detection gains. This analysis in Nature Medicine underscores that MCED technology is advancing faster than the outcomes evidence needed to guide responsible deployment — a pattern that warrants measured optimism rather than premature consensus.